Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 fidrisertib dose-regimen study in fibrodysplasia ossificans progressiva
NL-OMON59396Phase 2Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Fidrisertib in fibrodysplasia ossificans progressiva (FOP) (3 arms), sponsored by Clementia Pharmaceuticals Inc. Primary endpoints: Annualized change from baseline in heterotopic ossification volume and Safety and tolerability. Started Jan 2023; status: completed.
02
Drugs
Fidrisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NL-OMON59396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59396.